|
1
|
Podgoreanu MV, White WD, Morris RW, et al;
Perioperative Genetics and Safety Outcomes Study (PEGASUS)
Investigative Team. Inflammatory gene polymorphisms and risk of
postoperative myocardial infarction after cardiac surgery.
Circulation. 114(1 Suppl): I275–I281. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nathoe HM, van Dijk D, Jansen EW, et al;
Octopus Study Group. A comparison of on-pump and off-pump coronary
bypass surgery in low-risk patients. N Engl J Med. 348:394–402.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Domenighetti AA, Wang Q, Egger M, Richards
SM, Pedrazzini T and Delbridge LM: Angiotensin II-mediated
phenotypic cardiomyocyte remodeling leads to age-dependent cardiac
dysfunction and failure. Hypertension. 46:426–432. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mazzolai L, Pedrazzini T, Nicoud F,
Gabbiani G, Brunner HR and Nussberger J: Increased cardiac
angiotensin II levels induce right and left ventricular hypertrophy
in normotensives mice. Hypertension. 35:985–991. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vickers C, Hales P, Kaushik V, Dick L,
Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, et al:
Hydrolysis of biological peptides by human angiotensin-converting
enzyme-related carboxypeptidase. J Biol Chem. 277:14838–14843.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Der Sarkissian S, Huentelman MJ, Stewart
J, Katovich MJ and Raizada MK: ACE2: A novel therapeutic target for
cardiovascular diseases. Prog Biophys Mol Biol. 91:163–198.
2006.PubMed/NCBI
|
|
7
|
Raizada MK and Ferreira AJ: ACE2: a new
target for cardiovascular disease therapeutics. J Cardiovasc
Pharmacol. 50:112–119. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Burrell LM, Risvanis J, Kubota E, et al:
Myocardial infarction increases ACE2 expression in rat and humans.
Eur Heart J. 26:369–375; discussion 322–324. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hamming I, Cooper ME, Haagmans BL, et al:
The emerging role of ACE2 in physiology and disease. J Pathol.
212:1–11. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Der Sarkissian S, Grobe JL, Yuan L,
Narielwala DR, Walter GA, Katovich MJ and Raizada MK: Cardiac
overexpression of angiotensin converting enzyme 2 protects the
heart from ischemia-induced pathophysiology. Hypertension.
51:712–718. 2008.PubMed/NCBI
|
|
11
|
Zhao YX, Yin HQ, Yu QT, et al: ACE2
overexpression ameliorates left ventricular remodeling and
dysfunction in a rat model of myocardial infarction. Hum Gene Ther.
21:1545–1554. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ortiz Pérez JT, Riera M, Genover XB, De
Caralt TM, et al: Serum ACE2 activity correlates with infarct size
and left ventricular dysfunction during acute myocardial
infarction. J Cardiovasc Magn Reson. 13(Suppl 1): P1422011.
|
|
13
|
Thygesen K, Alpert JS and White HD; Joint
ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial
Infarction. Universal definition of myocardial infarction. J Am
Coll Cardiol. 50:2173–2195. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang W, Huang W, Su S, Li B, Zhao W, Chen
S and Gu D: Association study of ACE2 (angiotensin I-converting
enzyme 2) gene polymorphisms with coronary heart disease and
myocardial infarction in a Chinese Han population. Clin Sci (Lond).
111:333–340. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kassiri Z, Zhong J, Guo D, et al: Loss of
angiotensin-converting enzyme 2 accelerates maladaptive left
ventricular remodeling in response to myocardial infarction. Circ
Heart Fail. 2:446–455. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Keidar S, Gamliel-Lazarovich A, Kaplan M,
et al: Mineralocorticoid receptor blocker increases
angiotensin-converting enzyme 2 activity in congestive heart
failure patients. Circ Res. 97:946–953. 2005. View Article : Google Scholar
|
|
17
|
Ferrario CM, Jessup J, Chappell MC, et al:
Effect of angiotensin.converting enzyme inhibition and angiotensin.
II receptor blockers on cardiac angiotensin.converting enzyme.2.
Circulation. 111:2605–2610. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alyanakian MA, Dehoux M, Chatel D, et al:
Cardiac troponin I in diagnosis of perioperative myocardial
infarction after cardiac surgery. J Cardiothorac Vasc Anesth.
12:288–294. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lim CC, Cuculi F, van Gaal WJ, et al:
Early diagnosis of perioperative myocardial infarction after
coronary bypass grafting: a study using biomarkers and cardiac
magnetic resonance imaging. Ann Thorac Surg. 92:2046–2053. 2011.
View Article : Google Scholar
|
|
20
|
Burchill LJ, Velkoska E, Dean RG, Griggs
K, Patel SK and Burrell LM: Combination renin-angiotensin system
blockade and angiotensin-converting enzyme 2 in experimental
myocardial infarction: implications for future therapeutic
directions. Clin Sci (Lond). 123:649–658. 2012. View Article : Google Scholar
|
|
21
|
Mahajan VS and Jarolim P: How to interpret
elevated cardiac troponin levels. Circulation. 124:2350–2354. 2011.
View Article : Google Scholar : PubMed/NCBI
|
